New Alzheimer's research suggests possible cause: The interaction of proteins in the brain

June 19, 2013

For years, Alzheimer's researchers have focused on two proteins that accumulate in the brains of people with Alzheimer's and may contribute to the disease: plaques made up of the protein amyloid-beta, and tangles of another protein, called tau.

But for the first time, an 's has looked closely at not the two proteins independently, but at the interaction of the two proteins with each other—in the of post-mortem Alzheimer's patients and in mouse brains with Alzheimer's disease. The research found that the interaction between the two proteins might be the key: as these interactions increased, the progression of Alzheimer's disease worsened.

The research, by Hemachandra Reddy, Ph.D., an associate scientist at the Oregon National Primate Research Center at Oregon Health & Science University, is detailed in the June 2013 edition of the Journal of Alzheimer's Disease.

Reddy's paper suggests that when the interaction between the phosphorylated tau and the amyloid-beta—particularly in its toxic form—happens at brain synapses, it can damage those synapses. And that can lead to cognitive decline in Alzheimer's patients.

"This complex formation between amyloid beta and tau—it is actually blocking the neural communication," Reddy said. "If we could somehow find a molecule that could inhibit the binding of these two proteins at the synapses, that very well might be the cure to Alzheimer's disease."

To conduct the research, Reddy and his team studied three different kinds of mice, who had been bred to have some of the brain characteristics of Alzheimer's disease, including having amyloid-beta and phosphorylated tau in their brains. Reddy also analyzed postmortem brain tissue from people who had Alzheimer's disease.

Using multiple antibodies that recognize amyloid-beta and phosphorylated tau, Reddy and Maria Manczak, Ph.D., a research associate in Reddy's laboratory, specifically looked for the evidence of the amyloid beta and phosphorylated tau interactions. They found amyloid-beta/tau complexes in the human Alzheimer's brain tissue and in the Alzheimer's disease mouse brains. The Reddy team also found much more of those amyloid-beta/tau complexes in brains where Alzheimer's disease had progressed the most.

Reddy found very little or no evidence of the same interaction in the "control" subjects—mice that did not have the Alzheimer's traits and human brain tissue of people who did not have Alzheimer's.

"So much Alzheimer's research has been done to look at amyloid-beta and tau," Reddy said. "But ours is the first paper to strongly demonstrate that yes, there is an amyloid-beta/phosphorylated tau interaction. And that interaction might be causing the synaptic damage and cognitive decline in persons with Alzheimer's disease."

Reddy and his lab are already working on the next crucial questions. One is to define the binding site or sites and exactly where within the neuron the interaction of amyloid-beta and first occurs. The second is to find a way to inhibit that interaction—and thus maybe prevent or slow the progression of Alzheimer's.

Explore further: Alzheimer's brain change measured in humans

Related Stories

Alzheimer's brain change measured in humans

June 12, 2013
Scientists at Washington University School of Medicine in St. Louis have measured a significant and potentially pivotal difference between the brains of patients with an inherited form of Alzheimer's disease and healthy family ...

Genetic markers ID second Alzheimer's pathway

April 4, 2013
Researchers at Washington University School of Medicine in St. Louis have identified a new set of genetic markers for Alzheimer's that point to a second pathway through which the disease develops.

Alzheimer's disease is associated with removal of the synaptic protein ADAM10

May 8, 2013
Alzheimer's disease is characterized by the accumulation of neurotoxic β-amyloid peptide (A-beta). ADAM10, a protein that resides in the neural synapses, has previously been shown to prevent the formation of A-beta.

Commonly-prescribed drugs may influence the onset and progression of Alzheimer's disease

June 12, 2013
Multiple drug classes commonly prescribed for common medical conditions are capable of influencing the onset and progression of Alzheimer's disease, according to researchers at The Mount Sinai Medical Center. The findings ...

A new strategy required in the search for Alzheimer's drugs?

May 24, 2013
In the search for medication against Alzheimer's disease, scientists have focused – among other factors – on drugs that can break down Amyloid beta (A-beta). After all, it is the accumulation of A-beta that causes the ...

Scientists gain new understanding of Alzheimer's trigger

May 2, 2012
A highly toxic beta-amyloid – a protein that exists in the brains of Alzheimer's disease victims – has been found to greatly increase the toxicity of other more common and less toxic beta-amyloids, serving as a ...

Recommended for you

Researchers reveal new details on aged brain, Alzheimer's and dementia

November 21, 2017
In a comprehensive analysis of samples from 107 aged human brains, researchers at the Allen Institute for Brain Science, UW Medicine and Kaiser Permanente Washington Health Research Institute have discovered details that ...

Dementia study sheds light on how damage spreads through brain

November 20, 2017
Insights into how a key chemical disrupts brain cells in a common type of dementia have been revealed by scientists.

Researchers describe new biology of Alzheimer's disease

November 20, 2017
In a new study, researchers from Boston University School of Medicine (BUSM) describe a unique model for the biology of Alzheimer's disease (AD) which may lead to an entirely novel approach for treating the disease. The findings ...

Study shows video games could cut dementia risk in seniors

November 16, 2017
Could playing video games help keep the brain agile as we age?

New player in Alzheimer's disease pathogenesis identified

November 14, 2017
Scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have shown that a protein called membralin is critical for keeping Alzheimer's disease pathology in check. The study, published in Nature Communications, ...

Biomarker may predict early Alzheimer's disease

November 10, 2017
Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified a peptide that could lead to the early detection of Alzheimer's disease (AD). The discovery, published in Nature Communications, may ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

PPihkala
not rated yet Jun 19, 2013
It looks like someone is asking the right questions and therefore getting forward leading answers.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.